Thrombospondin-4 has emerged to be a promising therapy target for both limb-girdle muscular dystrophy type 2F and Duchenne muscular dystrophy, as its overexpression mitigated dystrophic phenotype in mouse models of these muscular dystrophies. The gene discussed is THBS4; the disease is autosomal recessive limb-girdle muscular dystrophy type 2F.